The approval follows FDA Breakthrough Therapy Designation in March 2018 and Priority Review Designation of the New Drug Application submitted in September 2018. The Janssen Pharmaceutical Companies of ...
Prescribing newly FDA-approved drugs may take a long time before patients can start taking them, so experts told CURE® why. For patients with bladder cancer, being prescribed certain drugs may “take a ...
Johnson & Johnson's confidence in its bladder cancer therapy TAR-200 – dented by a negative phase 3 readout last year – seems to be justified. New data from the SunRISe-1 study of TAR-200 in patients ...
The checkpoint-inhibitor refractory cancer market is anticipated to witness significant growth and evolution throughout the forecast period, driven by the widespread adoption of immune checkpoint ...
FGFR3-targeted therapies and the move of ADCs into muscle-invasive disease drive urothelial carcinoma growth across the US, EU4, UK and Japan.Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Urothelial ...
Links to Health Canada Notices of Compliance with conditions to market drugs, including fact sheets, letters to health professionals, letters to the public and qualifying notices ...
Monograph label safety assessment update from Health Canada ...
As part of the Federal Department of Home Affairs, the Federal Office of Public Health (FOPH) is responsible for public health in Switzerland; it develops Switzerland’s health policy and works to ...
Immune checkpoint inhibitors like Keytruda (pembrolizumab) are usually given as injections. Targeted therapies, such as Balversa (erdafitinib), are often taken as oral pills. Chemotherapies like ...
- Response seen even after treatment with Padcev and FGFR inhibitor treatment, with urothelial carcinoma patients sustaining it for over 6 months - No DLT even as dose escalates to 7 mg/kg – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results